Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC cut its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 31.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 19,065 shares of the company’s stock after selling 8,645 shares during the quarter. Guggenheim Capital LLC’s holdings in Twist Bioscience were worth $886,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. Barclays PLC increased its holdings in shares of Twist Bioscience by 214.8% in the third quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after purchasing an additional 104,420 shares during the period. Avanza Fonder AB acquired a new position in Twist Bioscience in the 4th quarter worth approximately $1,059,000. Principal Financial Group Inc. raised its position in Twist Bioscience by 67.5% during the 3rd quarter. Principal Financial Group Inc. now owns 205,864 shares of the company’s stock worth $9,301,000 after buying an additional 82,953 shares during the last quarter. Oddo BHF Asset Management Sas acquired a new stake in Twist Bioscience during the 3rd quarter valued at approximately $3,302,000. Finally, Vanguard Group Inc. grew its position in Twist Bioscience by 3.4% during the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock valued at $269,860,000 after buying an additional 189,791 shares during the period.

Insider Transactions at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the business’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total transaction of $156,202.20. Following the completion of the transaction, the director now directly owns 18,173 shares of the company’s stock, valued at approximately $965,531.49. The trade was a 13.93 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total transaction of $256,620.00. Following the sale, the chief executive officer now owns 667,318 shares in the company, valued at $32,932,143.30. The trade was a 0.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,374 shares of company stock valued at $955,871. 3.01% of the stock is currently owned by company insiders.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $37.62 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The company has a market cap of $2.24 billion, a P/E ratio of -11.13 and a beta of 2.34. The stock has a 50-day moving average of $39.95 and a two-hundred day moving average of $44.28. Twist Bioscience Co. has a 1-year low of $29.76 and a 1-year high of $60.90.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. The firm had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.75) earnings per share. As a group, analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on TWST shares. JPMorgan Chase & Co. lifted their target price on shares of Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Barclays reduced their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research report on Thursday, April 10th. Robert W. Baird increased their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. Guggenheim set a $50.00 target price on Twist Bioscience in a research report on Friday, March 28th. Finally, Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Twist Bioscience has an average rating of “Moderate Buy” and an average target price of $52.80.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.